Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis

Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2021-03, Vol.68 (3), p.e28852-n/a
Hauptverfasser:	Emberesh, Myesa, Rubinstein, Jeremy D., Young, Jennifer, Benoit, Stefanie W., Dandoy, Christopher E., Weiss, Brian D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Autografts Dialysis dinutuximab end‐stage renal disease Hematology Immunological tolerance Immunotherapy Kidney diseases Kidney transplantation Monoclonal antibodies Neuroblastoma Oncology Patients Pediatrics Targeted cancer therapy Thrombotic microangiopathy transplant‐associated thrombotic microangiopathy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!